Literature DB >> 18752070

The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia.

Huriye Balci1, Kadriye Akgun-Dar, Nurperi Gazioglu, Aysegul Kapucu, Murat Bolayirli, Buge Oz.   

Abstract

Leptin is a key mediator in the maintenance of neuroendocrine homeostasis. The aim of this study was to determine the changes in serum leptin, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), nitric oxide (NO) levels in patients with hyperprolactinemia. The study consists of 16 consecutive patients with high prolactin (PRL) levels (group I) and a control group of 11 normoprolactinemic patients (group II). Pituitary tumor tissues of patients in groups I and II were analyzed for immunohistochemical (IHC) expression of prolactin and leptin. Group I has significantly higher levels of leptin than group II (P < 0.001). There is a strong correlation between PRL and leptin concentrations in group I. However, there were no statistically significant differences for NO, TNF-alpha, IL-6 between the two groups. IHC staining showed that there was strong immunoreactivity for leptin protein in PRL-secreting pituitary adenomas. Double immunostaining of adenoma tissues with PRL and leptin showed that the adenoma cells expressed both. These findings together are suggestive that leptin co-secretion from a prolactinoma may be the cause of increased serum leptin concentration, independently from the peripheral action of prolactin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18752070     DOI: 10.1007/s11102-008-0140-4

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  27 in total

1.  Influence of intravenously administered leptin on nitric oxide production, renal hemodynamics and renal function in the rat.

Authors:  Jerzy Bełtowski; Jerzy Jochem; Grazyna Wójcicka; Krystyna Zwirska-Korczala
Journal:  Regul Pept       Date:  2004-08-15

Review 2.  Diagnosis and treatment of pituitary adenomas.

Authors:  P Chanson; S Salenave
Journal:  Minerva Endocrinol       Date:  2004-12       Impact factor: 2.184

3.  Mediators of inflammation in children with type I diabetes mellitus: cytokines in type I diabetic children.

Authors:  A B Erbağci; M Tarakçioğlu; Y Coşkun; E Sivasli; E Sibel Namiduru
Journal:  Clin Biochem       Date:  2001-11       Impact factor: 3.281

4.  Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo.

Authors:  V Mohamed-Ali; S Goodrick; A Rawesh; D R Katz; J M Miles; J S Yudkin; S Klein; S W Coppack
Journal:  J Clin Endocrinol Metab       Date:  1997-12       Impact factor: 5.958

5.  Prolactin receptor expression during adipocyte differentiation of bone marrow stroma.

Authors:  K M McAveney; J M Gimble; L Yu-Lee
Journal:  Endocrinology       Date:  1996-12       Impact factor: 4.736

Review 6.  Leptin, from fat to inflammation: old questions and new insights.

Authors:  Miguel Otero; Rocío Lago; Francisca Lago; Felipe F Casanueva; Carlos Dieguez; Juan Jesús Gómez-Reino; Oreste Gualillo
Journal:  FEBS Lett       Date:  2005-01-17       Impact factor: 4.124

Review 7.  Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus.

Authors:  A Rabinovitch; W L Suarez-Pinzon
Journal:  Biochem Pharmacol       Date:  1998-04-15       Impact factor: 5.858

8.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

9.  The release of leptin and its effect on hormone release from human pituitary adenomas.

Authors:  M Korbonits; M M Chitnis; M Gueorguiev; D Norman; N Rosenfelder; M Suliman; T H Jones; K Noonan; A Fabbri; G M Besser; J M Burrin; A B Grossman
Journal:  Clin Endocrinol (Oxf)       Date:  2001-06       Impact factor: 3.478

10.  Leptin and leptin receptor expression in normal and neoplastic human pituitary: evidence of a regulatory role for leptin on pituitary cell proliferation.

Authors:  L Jin; B G Burguera; M E Couce; B W Scheithauer; J Lamsan; N L Eberhardt; E Kulig; R V Lloyd
Journal:  J Clin Endocrinol Metab       Date:  1999-08       Impact factor: 5.958

View more
  4 in total

Review 1.  Leptin in hepatocellular carcinoma.

Authors:  Shen-Nien Wang; King-Teh Lee; Chen-Guo Ker
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

2.  Evaluation of body weight, insulin resistance, leptin and adiponectin levels in premenopausal women with hyperprolactinemia.

Authors:  Aysegul Atmaca; Birsen Bilgici; Gulcin Cengiz Ecemis; Ozgur Korhan Tuncel
Journal:  Endocrine       Date:  2013-03-26       Impact factor: 3.633

Review 3.  Metabolic effects of prolactin.

Authors:  Rosa Pirchio; Chiara Graziadio; Annamaria Colao; Rosario Pivonello; Renata S Auriemma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055

4.  Profile of leptin, adiponectin, and body fat in patients with hyperprolactinemia: Response to treatment with cabergoline.

Authors:  Nazir Ahmad Pala; Bashir Ahmad Laway; Raiz Ahmad Misgar; Zaffar Amin Shah; Tariq A Gojwari; Tariq A Dar
Journal:  Indian J Endocrinol Metab       Date:  2016 Mar-Apr
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.